Search

Your search keyword '"Agostini V"' showing total 344 results
Start Over Author "Agostini V"
344 results on '"Agostini V"'

1. Measurement of the cosmic ray flux by an ArduSiPM-based muon telescope in the framework of the Lab2Go project

Author

Agostini, V., Arcese, B., Ascani, N., Astone, P., Bocci, V., Caperna, S., Casaburo, F., Cerica, A., D'Auria, C., De Bonis, G., Deda, D., Di Mauro, F., Di Vico, A., Faccini, R., Frasca, L., Galuppi, G., Giovannetti, G., Iacoangeli, F., Ludovici, G., Martone, L., Marucci, B., Mizzoni, L., Moriconi, A., Organtini, G., Piacentini, F., Pietrobono, A., Pongelli, F., Severa, F., and Vona, D.

Subjects
Physics - Physics Education
Abstract

Whitin Istituto Nazionale di Fisica Nucleare (INFN) outreach activities, the Lab2Go project is of great significance. Its goal is involving high school teachers and students in several laboratory activities, aiming at increasing the weight of experimental contents in teaching and learning. In this article we present the measurement, carried out in the framework of the Lab2Go project, of the cosmic muon flux made by an ArduSiPM-based muon telescope.

Published
2023

2. A Ge.F.I. – ISFG European collaborative study on DNA identification of Cannabis sativa samples using a 13-locus multiplex STR method

Author

Di Nunzio, M., Agostini, V., Alessandrini, F., Barrot-Feixat, C., Berti, A., Bini, C., Bottinelli, M., Carnevali, E., Corradini, B., Fabbri, M., Fattorini, P., Garofano, P., Gino, S., Mameli, A., Marino, A., Previderè, C., Robino, C., Romano, C., Tozzo, P., Verzeletti, A., Buscemi, L., Gangitano, D., and Di Nunzio, C.

Published
2021
Full Text
View/download PDF

3. Automatic sleep scoring via deep learning: do it at home!

Author

Fiorillo, L., primary, Monachino, G., additional, Bechny, M., additional, Palo, G., additional, Samaras-Tsakiris, K., additional, du Toit, W., additional, Meier, E., additional, Melnykowycz, M., additional, Agostini, V., additional, and Faraci, F.D., additional

Published
2024
Full Text
View/download PDF

8. The Spectrum of the 2+1 Dimensional Gauge Ising Model

Author

Agostini, V., Carlino, G., Caselle, M., and Hasenbusch, M.

Subjects
High Energy Physics - Lattice, Condensed Matter, High Energy Physics - Theory
Abstract

We present a high precision Monte Carlo study of the spectrum of the $Z_2$ gauge theory in $2+1$ dimensions in the strong coupling phase. Using state of the art Monte Carlo techniques we are able to accurately determine up to three masses in a single channel. We compare our results with the strong coupling expansion for the lightest mass and with results for the universal ratio $\sigma/m^2$ determined for the $\phi^4$-theory. Finally the whole spectrum is compared with that obtained from the Isgur-Paton flux tube model and the spectrum of the $2+1$ dimensional $SU(2)$ gauge theory. A remarkable agreement between the Ising and SU(2) spectra (except for the lowest mass state) is found., Comment: uuencoded latex file of 22 pages plus 4 ps figures

Published
1996
Full Text
View/download PDF

9. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura

Author

Mancini, I., Ricaño‐Ponce, I., Pappalardo, E., Cairo, A., Gorski, M.M., Casoli, G., Ferrari, B., Alberti, M., Mikovic, D., Noris, M., Wijmenga, C., Peyvandi, F., Rinaldi, E., Melpignano, A., Campus, S., Podda, R.A., Caria, C., Caddori, A., Di Francesco, E., Giuffrida, G., Agostini, V., Roncarati, U., Mannarella, C., Fragasso, A., Podda, G.M., Bertinato, E., Cerbone, A.M., Tufano, A., Loffredo, G., Poggi, V., Pizzuti, M., Re, G., Ronchi, M., Codeluppi, K., Facchini, L., De Fanti, A., Amarri, S., Trisolini, S.M., Capria, S., Aprile, L., Defina, M., and Cerù, S.

Published
2016
Full Text
View/download PDF

14. Additional file 1 of Muscle synergies for the control of single-limb stance with and without visual information in young individuals

Author

Labanca, L., Ghislieri, M., Knaflitz, M., Barone, G., Bragonzoni, L., Agostini, V., and Benedetti, M. G.

Subjects
genetic structures, eye diseases
Abstract

Additional file 1. Example of muscle synergies in one of the participants. Activation coefficients and weight vectors obtained from a representative healthy subject of the sample population considering two different task conditions: eyes open and eyes closed conditions

Published
2021
Full Text
View/download PDF

17. The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age

Author

Agosti, P, Mancini, I, Artoni, A, Ferrari, B, Pontiggia, S, Trisolini, Sm, Facchini, L, Peyvandi, F, Capria, S, Codeluppi, K, Rinaldi, E, Pastore, D, Campus, S, Podda, Ra, Caria, C, Caddori, A, Nicolosi, D, Giuffrida, G, Agostini, V, Roncarati, U, Mannarella, C, Fragasso, A, Podda, Gm, Birocchi, S, Cerbone, Am, Tufano, A, Loffredo, G, Menna, G, Pizzuti, M, Ronchi, M, De Fanti, A, Amarri, S, Defina, M, Bocchia, M, Ceru, S, Gattillo, S, Agosti, P., Mancini I., Artoni A., Ferrari B., Pontiggia S., Trisolini S. M., Facchini L., Peyvandi F., and Tufano, A.

Subjects
medicine.medical_specialty, Thrombotic microangiopathy, ADAMTS13 Protein, Hemorrhage, Disease, 030204 cardiovascular system & hematology, Kidney, Adamts13 activity, 03 medical and health sciences, 0302 clinical medicine, Elderly, Older patients, Internal medicine, medicine, Humans, Registries, Acute thrombotic thrombocytopenic purpura management, ADAMTS13, Rare disease, Aged, Acquired Thrombotic Thrombocytopenic Purpura, Purpura, Thrombotic Thrombocytopenic, business.industry, Hematology, Microangiopathic hemolytic anemia, medicine.disease, Cross-Sectional Studies, 030220 oncology & carcinogenesis, Female, business
Abstract

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare life-threatening thrombotic microangiopathy (TMA) affecting more frequently women of 30–50 years of age. There is scarce information on the clinical features of aTTP occurring in the elderly. Our goal was to evaluate the impact of an elderly-onset disease on the expression, severity and management of aTTP. Materials and methods: We performed a cross-sectional study of patients enrolled in the Milan TTP Registry (www.ttpdatabase.org) after a first acute episode of aTTP from January 2002 to March 2018. The aTTP diagnosis was suspected on the basis of the presence of thrombocytopenia and microangiopathic hemolytic anemia with no alternative causes, and was confirmed centrally by a severe plasma deficiency of ADAMTS13 activity (

Published
2020

31. Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group

Author

Poole D., Cortegiani A., Chieregato A., Russo E., Pellegrini C., De Blasio E., Mengoli F., Volpi A., Grossi S., Gianesello L., Orzalesi V., Fossi F., Chiara O., Coniglio C., Gordini G., Blasio D., Nardi G., Agostini V., Bini G., Cimbanassi S., Cingolani E., Monesi A., Sanson G., Tacconi C., Poole D., Cortegiani A., Chieregato A., Russo E., Pellegrini C., De Blasio E., Mengoli F., Volpi A., Grossi S., Gianesello L., Orzalesi V., Fossi F., Chiara O., Coniglio C., Gordini G., Blasio D., Nardi G., Agostini V., Bini G., Cimbanassi S., Cingolani E., Monesi A., Sanson G., Tacconi C., Poole, D., Cortegiani, A., Chieregato, A., Russo, E., Pellegrini, C., De Blasio, E., Mengoli, F., Volpi, A., Grossi, S., Gianesello, L., Orzalesi, V., Fossi, F., Chiara, O., Coniglio, C., Gordini, G., Nardi, G., Agostini, V., Cimbanassi, S., Cingolani, E., Monesi, A., Sanson, G., and Tacconi, C.

Subjects
Tranexamic acid, Physiology, Glycobiology, lcsh:Medicine, Cardiovascular Medicine, Pathology and Laboratory Medicine, Biochemistry, Vascular Medicine, law.invention, Database and Informatics Methods, Fresh frozen plasma, 0302 clinical medicine, Randomized controlled trial, Coagulopathy, Animal Cells, law, Antifibrinolytic agent, Fibrinogen, Medicine and Health Sciences, 030212 general & internal medicine, Database Searching, lcsh:Science, Multidisciplinary, Plasma Exchange, Hematology, Blood Coagulation Disorders, Clinical Laboratory Sciences, Antifibrinolytic Agents, Body Fluids, Blood, trauma, Tranexamic Acid, Cardiovascular Diseases, Research Design, Meta-analysis, Observational Studies, Anatomy, Cellular Types, Research Article, Platelets, medicine.medical_specialty, Death Rates, Hemorrhage, Blood Component Transfusion, Research and Analysis Methods, External validity, 03 medical and health sciences, Signs and Symptoms, Population Metrics, Diagnostic Medicine, medicine, Humans, Blood Transfusion, Mortality, Intensive care medicine, Blood Coagulation, Wounds and Injuries, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), Demography, Glycoproteins, Blood Cells, Population Biology, Coagulation Disorders, Transfusion Medicine, business.industry, lcsh:R, Bleeding, Biology and Life Sciences, 030208 emergency & critical care medicine, Cell Biology, medicine.disease, Surgery, People and Places, lcsh:Q, Observational study, Packed red blood cells, business
Abstract

Background Traumatic coagulopathy is thought to increase mortality and its treatment to reduce preventable deaths. However, there is still uncertainty in this field, and available literature results may have been overestimated. Methods We searched the MEDLINE database using the PubMed platform. We formulated four queries investigating the prognostic weight of traumatic coagulopathy defined according to conventional laboratory testing, and the effectiveness in reducing mortality of three different treatments aimed at contrasting coagulopathy (high fresh frozen plasma/packed red blood cells ratios, fibrinogen, and tranexamic acid administration). Randomized controlled trials were selected along with observational studies that used a multivariable approach to adjust for confounding. Strict criteria were adopted for quality assessment based on a two-step approach. First, we rated quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Then, this rating was downgraded if other three criteria were not met: high reporting quality according to shared standards, absence of internal methodological and statistical issues not detailed by the GRADE system, and absence of external validity issues. Results With few exceptions, the GRADE rating, reporting and methodological quality of observational studies was “very low”, with frequent external validity issues. The only two randomized trials retrieved were, instead, of high quality. Only weak evidence was found for a relation between coagulopathy and mortality. Very weak evidence was found supporting the use of fibrinogen administration to reduce mortality in trauma. On the other hand, we found high evidence that the use of 1:1 vs. 1:2 high fresh frozen plasma/packed red blood cells ratios failed to obtain a 12% mortality reduction. This does not exclude lower mortality rates, which have not been investigated. The use of tranexamic acid in trauma was supported by “high” quality evidence according to the GRADE classification but was downgraded to “moderate” for external validity issues. Conclusions Tranexamic acid is effective in reducing mortality in trauma. The other transfusion practices we investigated have been inadequately studied in the literature, as well as the independent association between mortality and coagulopathy measured with traditional laboratory testing. Overall, in this field of research literature quality is poor.

Published
2016

47. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera

Author

Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, Barbui, T, Finazzi, G, Pusterla, S, Falanga, A, Galli, M, Wadenvik, H, Gastl, G, Ludescher, C, Lutz, D, Girschikofsky, M, Michlmayr, G, Rechberger, E, Niessner, H, Ivansich, E, Rain, Jd, Chommienne Thomas, C, Hehlmann, R, Engelich, G, Kohne, E, Kramer, A, Christakis, Ji, Papaioannou, M, Gerotziafas, G, O'Donnell, R, Bennett, M, Lugassy, G, Ellis, M, Eldor, A, Naparstek, E, Marilus, R, Leoni, P, Rupoli, S, Scortechini, Ar, Agostini, V, Volpe, E, Calmieri, F, Volpe, A, Storti, G, Ciampa, A, Dammacco, F, Lauta, Vm, Ranieri, G, Rizzi, R, Orsola, S, Tura, S, Finelli, C, Marino, G, Rossi, G, Almici, C, Capucci, A, Zanetti, F, Giustolisi, R, Cacciola, Rr, Cacciola, E, Peta, A, Magro, D, Frigerio, G, Alberio, F, Beretta, A, Bonferroni, M, Raviolo, A, Ferrini, Prl, Grossi, A, Fabbri, A, Nardelli, S, Centra, A, Musolino, C, Bellomo, G, Trincali, O, Spatari, Giovanna, Foa, P, Gerli, G, Carraro, Mc, Zanella, A, Lurlo, A, Barraco, F, Torelli, G, Marietta, M, Pogliani, E, Miccolis, Ir, La Rocca, A, Puglisi, A, Sardeo, G, Rotoli, B, Martinelli, V, Ciancia, R, Cardarelli, A, Cimino, R, Fasanaro, A, Randi, Ml, Rizzoli, V, Caramatti, C, Gaeta, L, Lazzarino, M, Passamonti, F, Lazzola, M, Malabarba, L, Natale, D, Pulini, S, Davi, G, Gugliotta, L, Ilariucci, F, De Candia, E, Eugenio, S, Amadori, S, Buccisano, F, Mandelli, F, Montefusco, E, Petti, Mc, Spadea, A, Carotenuto, M, Morelli, A, Nobile, M, Longinotti, M, Pardini, Sm, Lauria, F, Buccalossi, A, Gentili, S, Mazza, P, Cervellera, M, Maggi, A, Di Francesco, A, Pasqualoni, E, Chisesi, T, Polacco, A, Capnist, G, Rodeghiero, F, Ruggeri, M, Arrizabalaga, B, Remacha, A, De Mendiguren, Bp, Hernandez Nieto, L, Hernandez Garcia, Mt, Gonzalez Brito, G, Machado, P, Garcia, G, Villegas, A, Pena, A, Fernandez, Ag, Carbonell, F, Del Arco, A, Back, H, Stenke, L, Hansen, S, Larsson, G, Stromblad, G, Lauri, B, Ryden, Bo, Linder, O, Lundholm, Bg, Lannemyr, O, Strandberg, M, Andreasson, B, Stockelberg, D, Pasquariello, F, Tichelli, A, Otremba, B, Hinrichs, Hf, Weber Stadelmann, W, Bareford, D, Oscier, Dg, Bowey, N, Taylor, Pc, de Gaetano, G, Najean, Y, Pearson, Tc, Di Blasio, A, Atashkar, S, Mari, E, Tamayo, D, Borelli, G, Ferri, B, Marfisi, Rm, Olivieri, M, Polidoro, A, Spoltore, R, Levantesi, G, Di Mascio, R, Miceli, G, Sperti, G, Correale, E, Vermjlen, J, and Collins, R.

Subjects
Aspirin, medicine.medical_specialty, business.industry, food and beverages, General Medicine, medicine.disease, Thrombosis, Pulmonary embolism, Venous thrombosis, Polycythemia vera, Relative risk, Internal medicine, Anesthesia, Cardiology, Medicine, Myocardial infarction, business, Contraindication, medicine.drug
Abstract

background The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. methods We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. results Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). conclusions Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.

Published
2004

48. Metronomic capecitabine in advanced hepatocellualr cacinoma patients who have failed sorafenib: a phase II study

Author

De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G, and De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G

Subjects
Metronomic chemotherapy, sorafenib, advanced hepatocellular carcinoma, antiangiogenic activity
Published
2011

49. Metronomic capecitabine in advanced hepatocellular carcinoma patients who have failed sorafenib: a phase 2 study

Author

de Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, PISCAGLIA, FABIO, TREVISANI, FRANCO, Golfieri R, BOLONDI, LUIGI, PINNA, ANTONIO DANIELE, BIASCO, GUIDO, BRANDI, GIOVANNI, de Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, and Brandi G.

Published
2011

50. The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action

Author

MACCHINI, MARINA, BRANDI, GIOVANNI, TAVOLARI, SIMONA, DE ROSA, FRANCESCO, PATERINI, PAOLA, DI MARCO, MARIACRISTINA, DI CICILIA, ROBERTO, NOBILI, ELISABETTA, BIASCO, GUIDO, GUARNIERI, TIZIANA, Di Girolamo S, Agostini V, Vecchiarelli S, Macchini M, Brandi G, Tavolari S, Guarnieri T, de Rosa F, Paterini P, Di Girolamo S, Agostini V, Di Marco M, Vecchiarelli S, Di Cicilia R, Nobili E, and Biasco G.

Subjects
endocrine system diseases, Protease Inhibitor Gabexate Mesylate
Abstract

Context Pancreatic cancer cells produce various proteases involved in invasion, angiogenesis and metastatic spread. Gabexate mesylate (GM), a serine protease inhibitor, may reduce invasive capabilities and enhance chemotherapy effects. Objective To evaluate the effect of treatment with GM and gemcitabine (GEM), alone or combined. Materials and methods Studies have been performed on cancer cell lines PANC-1, SW1990 and endothelial cell EA.hy926. Treatment consisted of GM (50-100 µM for 24 h), alone or followed by GEM (250 µM for 24 h). Aspects studied included: cell viability (MTT assay), cell invasiveness and migration (Boyden chambers chemoinvasion and chemotaxis assay), angiogenesis (endothelial tube formation assay) and VEGF levels (ELISA) in EA.hy926 cell, MMP-2 and MMP-9 activity (gelatin zymography). Results Cell viability: this parameter decreased by 40% with GM alone only in EA.hy926 cells (P

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results